Amiodarone-induced thyrotoxicosis: A review

Canadian Journal of Cardiology

Volumn 25, Issue 7, 2009, Pages 421-424

  Tsang, Wendy ^a   Houlden, Robyn L ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

Amiodarone induced thyrotoxicosis; Colour flow Doppler sonography; Complications; Management; Treatment

Indexed keywords

AMIODARONE; ANTITHYROID AGENT; GLUCOCORTICOID; IODINE 131; LIOTHYRONINE; LITHIUM; POTASSIUM PERCHLORATE; PREDNISOLONE; THYROTROPIN; THYROXINE; ANTIARRHYTHMIC AGENT; VASODILATOR AGENT;

AGED; AMIODARONE INDUCED THYROTOXICOSIS TYPE 1; AMIODARONE INDUCED THYROTOXICOSIS TYPE 2; ANAMNESIS; ANGINA PECTORIS; CASE REPORT; COLOR ULTRASOUND FLOWMETRY; DIFFERENTIAL DIAGNOSIS; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEVER; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GOITER; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HEAT SENSITIVITY; HUMAN; HYPERHIDROSIS; IODINE 131 UPTAKE TEST; MALE; MUSCLE WEAKNESS; PHYSICAL EXAMINATION; RESTLESSNESS; REVIEW; SINUS TACHYCARDIA; THYROIDECTOMY; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; TREMOR; TYPE 1 AMIODARONE INDUCED THYROTOXICOSIS; TYPE 2 AMIODARONE INDUCED THYROTOXICOSIS; WEIGHT REDUCTION; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; GRAVES DISEASE; NODULAR GOITER; SUBACUTE THYROIDITIS;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; GOITER, NODULAR; GRAVES DISEASE; HUMANS; THYROIDITIS, SUBACUTE; THYROTOXICOSIS; VASODILATOR AGENTS;

EID: 67849099165     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(09)70512-4     Document Type: Review

References (28)

1. Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 2000;160:1741-8.
2. Martino E, Aghini-Lombardi F, Mariotti S, et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med 1984;101:28-34.
3. Bouvy ML, Heerdink ER, Hoes AW, Leufkens HG. Amiodaroneinduced thyroid dysfunction associated with cumulative dose. Pharmacoepidemiol Drug Saf 2002;11:601.
4. Kennedy RL, Griffiths H, Gray TA. Amiodarone and the thyroid. Clin Chem 1989;35:1882-7.
5. Roa RH. Iodine kinetic studies during amiodarone treatment. J Clin Endocrinol Metab 1986;62:563-8.
6. Pollak PT, Bouillon T, Shafer SL. Population pharmacokinetics of long-term oral amiodarone therapy. Clin Pharmacol Ther 2000;67:642-52.
7. Lambert MJ, Unger J, De Nayer P, et al. Are selective increases in serum thyroxine (T4) due to iodinated inhibitor of T4 monodeiodination indicative of hyperthyroidism? J Clin Endocrinol Metab 1982;55:1058-65.
8. Sogol PB, Hershman JM, Reed AW, et al. The effects of amiodarone on serum thyroid hormones and hepatic 5′-deiodinase. Endocrinology 1983;113:1464-9.
9. Chiovato L, Martino E, Tonacchera M, et al. Studies on the in vitro cytotoxic effects of amiodarone. Endocrinology 1994;134:2277-82.
10. Cardenas GA, Cabral JM, Leslie CA. Amiodarone-induced thyrotoxicosis: Diagnostic and therapeutic strategies. Cleve Clin J Med 2003;70:624-31.
11. Newman CM, Price A, Davies DW, et al. Amiodarone and the thyroid: A practical guide to the management of thyroid dysfunction induced by amiodarone therapy. Heart 1998;79:121-7.
12. Brennan MD, Erickson DZ, Carney JA, et al. Nongoitrous (type 1) amiodarone-associated thyrotoxicosis; evidence of follicular disruption in vitro and in vivo. Thyroid 1995;5:177.
13. Martino E, Aghini-Lombardi F, Lippi F, et al. Twenty-four hour radioactive iodine uptake in 35 patients with amiodarone associated thyrotoxicosis. J Nucl Med 1985;26:1402-7.
14. Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocrine Rev 2001;22:240-54.
15. Daniels GH. Amiodarone induced thyrotoxicosis. J Clin Endocrinol Metab 2001;86:3-8.
16. Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med 1997;126:63-73.
17. Ludica-Souza C. Amiodarone-induced thyroid dysfunction. Endocrinologist 1999;9:216-27.
18. Bartalena L, Grasso L, Brogioni S, et al. Serum interleukin-6 in amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 1994;789:423-7.
19. Bogazzi F, Martino E, Dell'Unto E, et al. Thyroid color flow Doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis. J Endocrinol Invest 2003;26:635.
20. Eaton SE, Euinton HA, Newman CM, et al. Clinical experience of amiodarone induced thryotoxicosis over a 3-year period: Role of colour-flow Doppler sonography. Clin Endocrinol 2002;56:33-8.
21. Wolf J. Perchlorate and the thyroid gland. Pharmacol Rev 1998;50:89-105.
22. Dickstein G, Schechner C, Adawi F, et al. Lithium treatment in amiodarone-induced thyrotoxicosis. Am J Med 1997;102:454-8.
23. Hermida JS, Jarry G, Tcheng E, et al. Radioiodine ablation of the thyroid to allow the reintroduction of amiodarone treatment in patients with a prior history of amiodarone-induced thyrotoxicosis. Am J Med 2004;116:345.
24. Matino E, Bartalena L, Mariotti S, et al. Radioactive iodine thyroid uptake in patients with amiodarone-iodine-induced thyroid dysfunction. Acta Endocrinol 1988;119:167-73.
25. Houghton SG, Farley DR, Brennan MD, et al. Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience. World J Surg 2004;28:1083-7.
26. Farwell AP, Abend SL, Huang SK, et al. Thyroidectomy for amiodarone-induced thyrotoxicosis. JAMA 1990;263:1526-8.
27. Williams M, Lo Gerfo P. Thyroidectomy using local anesthesia in critically ill patients with amiodarone-induced thyrotoxicosis: A review and description. Thyroid 2002;12:523-5.
28. Diamond TH, Rajagopal R, Ganda K, Manoharan A, Luk A. Plasmapheresis as a potential treatment option for amiodaroneinduced thyrotoxicosis. Int Med J 2004;34:369-70.